Clinical trials: Statin Intolerance, open to volunteers
Statin Therapy, Statin Adverse Reaction
DESIFOR-EXPAND (MHIF)
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
- Conditions
- Statin Therapy, Statin Adverse Reaction, Statin
- Trial name
- NCT06804980
- Testing
- Rosuvastatin (Crestor)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Minneapolis Heart Institute Foundation
Hyperlipidemia, Ursodeoxycholic Acid
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA.
- Conditions
- Hyperlipidemia, Ursodeoxycholic Acid, Statin Therapy, Glucose Intolerance
- Trial name
- URSTAR (NCT06684106)
- Testing
- Ursodeoxycholic acid (UDCA) 500 mg
- Where
- 2 sites in China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Drug Interactions, Primary Prevention
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals.
- Conditions
- Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering
- Trial name
- SOLVE-LDL-C (NCT06865885)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
- Trial name
- PCSK9-DUO (NCT07581808)
- Testing
- Inclisiran, Alirocumab
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.